CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 84 enrolled
Drug / intervention
GastimunHPdietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02721355
NCT02721355N/ACompleted
CompareCT.gov

Evaluation of a Health Food Supplement Containing Anti-Helicobacter Pylori Urease IgY Antibody on Patients With Chronic Gastritis in Hanoi, Vietnam

Immunology Research Institute in Gifu·interventional·Posted Mar 29, 2016·Updated Jan 28, 2021

In Brief

A clinical study evaluating GastimunHP for Chronic Gastritis Caused by Helicobacter Pylori. Completed, enrolled 84 participants across 1 site.

Detailed Summary

H. pylori positive patient volunteers that passed the selection criteria are recruited and divided into a test and a control group. Both groups are treated with a current treatment regime (EAC: Esomeprazole 40 mg/day; Clarithromycin 1000 mg/day; Amoxicillin 2000 mg/day) but only the test group received IgY-containing food supplement as an adjunctive measure for 15 days. The subjects are examined before and 4 weeks after the treatment initiation by Urea Breath Test (UBT) and gastro-endoscopy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Gastritis Caused by Helicobacter Pylori
CountriesVietnam
CollaboratorsDong Do Pharmaceutical Co.

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 29, 2016
Enrollment StartJun 1, 2013
Primary CompletionMay 1, 2016
Study CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 10.3 years ago

Interventions

GastimunHPdietary

Health food supplement containing specific IgY against urease of H. pylori